Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Revenue (2017 - 2025)

Historic Revenue for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $4.7 million.

  • Protagonist Therapeutics' Revenue rose 79.14% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.6 million, marking a year-over-year decrease of 3512.36%. This contributed to the annual value of $434.4 million for FY2024, which is 62405.5% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Revenue stood at $4.7 million for Q3 2025, which was up 79.14% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Revenue ranged from a high of $255.0 million in Q1 2024 and a low of $900000.0 during Q2 2022
  • Over the past 5 years, Protagonist Therapeutics' median Revenue value was $8.6 million (recorded in 2021), while the average stood at $45.6 million.
  • In the last 5 years, Protagonist Therapeutics' Revenue soared by 264691.36% in 2021 and then crashed by 8889.17% in 2025.
  • Protagonist Therapeutics' Revenue (Quarter) stood at $8.6 million in 2021, then skyrocketed by 1205.56% to $112.5 million in 2022, then crashed by 55.56% to $50.0 million in 2023, then soared by 230.0% to $165.0 million in 2024, then tumbled by 97.14% to $4.7 million in 2025.
  • Its Revenue stands at $4.7 million for Q3 2025, versus $5.5 million for Q2 2025 and $28.3 million for Q1 2025.